Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

Immunogenicity and Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With GSK Biologicals' DTaP Vaccine (Infanrix™) and Aventis Pasteur's Haemophilus b Conjugate Vaccine (ActHIB) in Healthy Children 15 Months of Age

This is a study to evaluate the immune response and safety of GSK Biologicals 2-dose inactivated hepatitis A vaccine when administered with a diphtheria, tetanus and pertussis combination (DTaP) vaccine and a Haemophilus influenza type B (Hib) vaccine in children 15 months of age. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Study Overview

• Status: Completed
• Conditions: Hepatitis A
• Intervention / Treatment: Biological: Havrix™; Biological: Infanrix™; Biological: ActHIB™

Detailed Description

An open, controlled comparison of Havrix™ administered alone or with Infanrix™ and ActHIB. The three groups evaluated are: 1) Havrix™ alone, 2) Havrix™ + Infanrix™ and ActHIB and 3) Infanrix™ and ActHIB followed by Havrix™ one month later.

• Study Type: Interventional
• Enrollment (Actual): 468
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85029
      • GSK Investigational Site
  • California
    • Oakland, California, United States, 94612
      • GSK Investigational Site
    • San Ramon, California, United States, 94583
      • GSK Investigational Site
  • Delaware
    • Wilmington, Delaware, United States, 19810
      • GSK Investigational Site
  • Florida
    • Pembroke Pines, Florida, United States, 33027
      • GSK Investigational Site
  • Georgia
    • Martinez, Georgia, United States, 30907
      • GSK Investigational Site
  • Iowa
    • Waterloo, Iowa, United States, 50702
      • GSK Investigational Site
  • Louisiana
    • Bossier City, Louisiana, United States, 71111
      • GSK Investigational Site
  • New Jersey
    • Long Branch, New Jersey, United States, 07740
      • GSK Investigational Site
  • New York
    • Ithaca, New York, United States, 14850
      • GSK Investigational Site
  • North Dakota
    • Bismarck, North Dakota, United States, 58501
      • GSK Investigational Site
  • Ohio
    • Youngstown, Ohio, United States, 44501
      • GSK Investigational Site
  • Pennsylvania
    • Bellevue, Pennsylvania, United States, 15202
      • GSK Investigational Site
    • Hershey, Pennsylvania, United States, 17033
      • GSK Investigational Site
    • Pittsburgh, Pennsylvania, United States, 15241
      • GSK Investigational Site
    • Pittsburgh, Pennsylvania, United States, 15213
      • GSK Investigational Site
  • South Carolina
    • Charleston, South Carolina, United States, 29425
      • GSK Investigational Site
  • Texas
    • Beaumont, Texas, United States, 77701
      • GSK Investigational Site
    • Dallas, Texas, United States, 75235
      • GSK Investigational Site
  • Virginia
    • Danville, Virginia, United States, 24549
      • GSK Investigational Site
    • Mechanicsville, Virginia, United States, 23111
      • GSK Investigational Site
  • Wisconsin
    • La Crosse, Wisconsin, United States, 54601
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years to 2 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects whose parents/guardians are believed by the investigator to be willing to comply with the requirements of the protocol
• A male or female child 12 or 13 months of age at the time of entry into the Enrolment Phase,
• Subjects must have previously received three doses each of DTaP and Hib vaccines during the first year of life. The three doses of DTaP vaccine must have been administered as either Infanrix™ or Pediarix™ and the three doses of Hib vaccine must have been administered as ActHIB™, HibTITER™, OmniHIB™.
• Subjects who, at 15 months of age, will have had at least six months elapse since their third dose of Infanrix™ or Pediarix™,
• Written informed consent obtained from the parents or guardian of the subject,
• Free of obvious health problems as established by medical history and history-directed physical examination before entering into the study, and
• Parents/guardian of the subject must have a telephone or be able to be contacted by telephone.

Exclusion Criteria:

• Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 31 days preceding the first dose of study vaccine, or planned use during the study period,
• Chronic administration (defined as more than 14 days) of immuno-suppressant or other immune-modifying drugs within six months prior to vaccination or planned administration at any time during the study period.
• Planned administration or administration of any vaccine not foreseen by the study protocol during the period 42 days before and 31 days after each dose of study vaccine(s).
• Previous vaccination against DTaP using a commercially-available brand other than Infanrix™ or Pediarix™ or against Hib using a commercially-available brand other than ActHIB™, HibTITER™ or OmniHIB™.
• Previous vaccination with more than three doses of DTaP-containing vaccines or more than three doses of Hib-containing vaccines.
• Previous vaccination against hepatitis A,
• History or known exposure to hepatitis A,
• History of diphtheria, tetanus, pertussis and/or Haemophilus influenza type b,
• Known exposure to diphtheria, tetanus, pertussis and/or Haemophilus influenza type b within 31 days prior to the start of the study,
• History of non-response to any vaccine in the current routine immunization schedule,
• Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection,
• A family history of congenital, hereditary or infectious immunodeficiency or parental risk factors for HIV infection,
• History of allergic disease/reactions or hypersensitivity likely to be exacerbated by any component of Havrix™, Infanrix™ or ActHIB™ including 2-phenoxyethanol, neomycin and gelatin,
• History of hypersensitivity/allergic reaction to latex
• Major congenital defects or serious chronic illness,
• History of any neurologic disorder
• Acute disease at the time of vaccination.
• Administration of immunoglobulins and/or any blood products within three months prior to the first dose of study vaccine or planned administration at any time during the entire study period, i.e., the Enrolment Phase, the Active Phase and the Extended Safety Follow-up Phase

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Havrix Group; Subjects received one dose of Havrix at Day 0 followed by a second dose of Havrix at Month 6-9.	Biological: Havrix™; 2 intramuscular injections, 6 months apart
Experimental: Infanrix + ActHIB→Havrix Group; Subjects received Infanrix co-administered with ActHIB at Day 0, followed by one dose of Havix at Day 30 and a second dose of Havrix at Month 7-10.	Biological: Havrix™; 2 intramuscular injections, 6 months apart; Biological: Infanrix™; 1 intramuscular injection; Biological: ActHIB™; 1 intramuscular injection
Active Comparator: Havrix + Infanrix + ActHIB Group; Subjects received one dose of Havrix co-administered with Infanrix and ActHIB vaccines at Day 0 followed by a second dose of Havrix at Month 6-9.	Biological: Havrix™; 2 intramuscular injections, 6 months apart; Biological: Infanrix™; 1 intramuscular injection; Biological: ActHIB™; 1 intramuscular injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Seropositive Subjects for Anti-hepatitis A Virus (HAV) Antibodies Following the Second Dose of Havrix	Subjects are defined as being anti-HAV seropositive if their anti-HAV antibody concentration is ≥ 15 milli-International Units per milliliter (mIU/mL).	31 days following the second dose of Havrix™
Number of Anti-diphtheria, Anti-tetanus and Anti-polyribosylribitol Phosphate (PRP) Seroprotected Subjects	Subjects are defined as being anti-diphtheria, anti-tetanus and anti-PRP seroprotected if their anti-diphtheria and anti-tetanus antibody concentration is ≥ 0.1 International Units per milliliter (IU/mL) and if their anti-PRP antibody concentration is ≥ 1 microgram per milliliter (μg/mL), respectively.	31 days following the administration of Infanrix™ and ActHIB
Number of Vaccine Responders for Anti-pertussis Toxoid (PT), Anti-filamentous Hemagglutinin (FHA) and Anti-pertactin (PRN)	Subjects are considered as being vaccine responders if they were initially seronegative and become seropositive (≥ 5 Enzyme Linked Immunosorbent Assay Units per Milliliter (EL.U/mL)), or were initially seropositive and have a 2-fold increase above pre-study concentrations.	31 days following the administration of Infanrix™ and ActHIB

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Anti-diphtheria and Anti-tetanus Antibody Geometric Mean Concentrations (GMC)	GMCs are expressed as International Units per milliliter (IU/mL).	31 days following the administration of Infanrix™ and ActHIB
Anti-polyribosylribitol Phosphate (PRP) Antibody Geometric Mean Concentrations (GMC)	GMCs are expressed as microgram/milliliter (µg/mL).	31 days following the administration of Infanrix™ and ActHIB
Number of Subjects Seropositive for Anti-pertussis Toxoid (PT), Anti-filamentous Hemagglutinin (FHA), Anti-pertactin (PRN) and Anti-polyribosylribitol Phosphate (PRP)	Seropositivity is defined as antibody concentrations ≥ 5 Enzyme Linked Immunosorbent Assay Units per Milliliter (EL.U/mL) for anti-PT, anti-FHA and anti-PRN antibodies and as antibody concentrations ≥ 0.15 microgram/milliliter (µg/mL) for anti-PRP antibodies.	31 days following the administration of Infanrix™ and ActHIB
Number of Seropositive Subjects for Anti-hepatitis A Virus (HAV) Antibodies Following the First Dose of Havrix	Subjects are defined as being anti-HAV seropositive if their anti-HAV antibody concentration is ≥ 15 milli-International Units per milliliter (mIU/mL).	31 days following the first dose of Havrix™
Anti-hepatitis A Virus (HAV) Antibody Geometric Mean Concentrations (GMC) Following the First Dose of Havrix	Anti-hepatitis A (HAV) antibody geometric mean concentrations (GMC) are expressed as milli-International Units per milliliter (mIU/mL).	31 days following the first dose of Havrix™
Anti-hepatitis Virus A (HAV) Antibody Geometric Mean Concentrations (GMC) Following the Second Dose of Havrix	Anti-hepatitis A (HAV) antibody geometric mean concentrations (GMC) are expressed as milli-International Units per milliliter (mIU/mL).	31 days following the second dose of Havrix™
Number of Subjects With Vaccine Response to Havrix™.	Vaccine response to Havrix is defined as post-vaccination anti-HAV antibody concentrations ≥ 15 mIU/mL in initially seronegative subjects or a ≥ 2-fold increase above the pre-vaccination anti-HAV antibody concentration in initially seropositive subjects.	31 days following the second dose
Number of Subjects Reporting Solicited Local Adverse Events (AEs)	Solicited local AEs assessed include pain, redness and swelling. Data across doses are presented in the table.	4-day period following each dose of study vaccine(s)
Number of Subjects Reporting Solicited General Adverse Events (AEs)	Solicited general AEs assessed include drowsiness, axillary fever ≥ 37.5°C, irritability and loss of appetite. Data across doses are presented in the table.	4-day period following each dose of study vaccine(s)
Number of Subjects Reporting Unsolicited Adverse Events (AEs)	An Adverse Event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.	31-day period following each dose of study vaccine(s)
Number of Subjects Reporting Serious Adverse Events (SAEs), New Chronic Illnesses and Medically Significant Events	Since the related information about medically significant events was not specifically collected and new chronic illnesses were only collected in the extended safety follow-up phase, all unsolicited adverse events (AEs) throughout the study are reported in the table without identifying which event was a medically significant or new chronic illness.	Active Phase and the 6-months Extended Safety Follow-up (ESFU) Phase.

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

General Publications

• Trofa AF, Klein NP, Paul IM, Michaels MG, Goessler M, Chandrasekaran V, Blatter M. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age. Pediatr Infect Dis J. 2011 Sep;30(9):e164-9. doi: 10.1097/INF.0b013e31821b8a7d.

Helpful Links

• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

Study record dates

Study Major Dates

• Study Start: November 11, 2003
• Primary Completion (Actual): December 3, 2007
• Study Completion (Actual): December 3, 2007

Study Registration Dates

• First Submitted: September 15, 2005
• First Submitted That Met QC Criteria: September 15, 2005
• First Posted (Estimate): September 20, 2005

Study Record Updates

• Last Update Posted (Actual): August 20, 2018
• Last Update Submitted That Met QC Criteria: July 2, 2018
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Keywords: Hepatitis A
• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Liver Diseases; Hepatitis, Viral, Human; Enterovirus Infections; Picornaviridae Infections; Hepatitis; Hepatitis A
• Other Study ID Numbers: 208109/232

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Study Data/Documents

1. Study Protocol
   Information identifier: 208109/232
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
2. Informed Consent Form
   Information identifier: 208109/232
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
3. Individual Participant Data Set
   Information identifier: 208109/232
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
4. Dataset Specification
   Information identifier: 208109/232
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
5. Statistical Analysis Plan
   Information identifier: 208109/232
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
6. Clinical Study Report
   Information identifier: 208109/232
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register